Determination of Plasma Concentrations of Cyclandelate and Mandelic Acid in Patients with Generalized Atherosclerotic Vasculopathy Treated with Oral Cyclandelate
Restricted accessResearch articleFirst published online July, 1990
Determination of Plasma Concentrations of Cyclandelate and Mandelic Acid in Patients with Generalized Atherosclerotic Vasculopathy Treated with Oral Cyclandelate
Cyclandelate, a vasoactive substance consisting of the mandelic acid ester of 3,3,5-trimethylcyclohexanol, was administered to 10 patients with cerebrovascular and/or peripheral vascular disease. Blood specimens were collected at 1 − 6 h after oral administration of 1600 mg cyclandelate, and the ester and acid were extracted from plasma in acid medium using n-hexane/isopropyl alcohol. The concentrations were determined by a high-performance liquid chromatography isocratic system. The highest plasma cyclandelate concentrations were detected at the third hour, whereas plasma mandelic acid concentrations were still increasing 6 h after administration.
TimmermanH, WallRJ, BenyonJSE: Cyclospasmol: new insights into basic mechanisms in relation to clinical effects. Br J Clin Pract1984; 38: 1–79.
2.
BallJAC, TaylorAR: Effect of cyclandelate on mental functions and cerebral blood flow in elderly patients. Br Med J1967; iii: 525–528.
3.
RaoDB: Cyclandelate in the treatment of senile mental changes: a double-blind evaluation. J Am Geriatr Soc1977; 25: 548–551.
4.
SouranderL, BlakemoreCB: Effects of Cyclospasmol upon sensory parameters in patients recovering from cerebrovascular accidents. Angiology1978; 29: 133–138.
5.
KuhnRA: Effect of cyclandelate upon cerebral flow in patients with stroke. Angiology1966; 17: 422–430.
6.
Van WijkTD: The treatment of peripheral vascular diseases with Cyclospasmol. Angiology1953; 4: 103–113.
7.
RavinaA: Traitement des troubles de la circulation périphérique par l'ester amygdalique du 3,3,5-trimethyl-cyclohexanol. Presse Med1963; 71: 727–728.
8.
ReichT: Cyclandelate: effect on circulatory measurements and exercise tolerance in chronic arterial insufficiency of the lower limbs. J Am Geriatr Soc1977; 25: 202–205.
9.
ForconiS, CappelliR, PieragalliD: Effect of a single administration of cyclandelate on some theological and peripheral haemodynamic parameters of peripheral arterial disease patients. In: Microcirculation – an Update (TsuchiyaM, AsanoM, MishimaY, eds) Amsterdam: Elsevier, 1987; pp 537–538.
10.
Van den HovenWE, HallDWR: Inhibition of human platelet functions by cyclandelate. Drugs1987; 33 (2): 41–52.
11.
Van den HovenWE, HallDWR, BurnsJW: Cyclandelate and a number of its metabolites inhibit discocyte echinocyte transformations of human erythrocytes. Br J Clin Pract1984; 38: 26–29.
12.
HallDWR, Van den HovenWE: Influence of cyclandelate on in vitro red blood cell deforma-bility. Drugs1987; 33 (2): 30–40.
13.
Van den HovenWE, HallDWR, BurnsJW: Inhibitory action of cyclandelate and a number of its metabolites on cyclic AMP phosphordiesterase. Br J Clin Pract1984; 34: 20–24.
14.
AndermannG, DietzM: Simultaneous determination of cyclandelate and its metabolite in human plasma by capillary column gas – liquid chromatography. J Chromatogr1981; 223: 365–370.
15.
AndermannG, DietzM: Dosage plasmatique et urinaire du 3,3,5-triméthylcyclohexanol libré et conjuguéJ Chromatogr1983; 272: 299–305.
